Advisors Asset Management Inc. Buys 75,409 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Vertex Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Advisors Asset Management initiated a Vertex Pharmaceuticals position, buying 75,409 shares worth approximately $39.4 million in the third quarter. Institutional investors collectively own 90.96% of the stock.
  • Vertex reported quarterly revenue of $3.44 billion, up 11.8% year over year and above estimates, but earnings per share of $4.76 fell short of the $4.82 consensus.
  • Analyst sentiment is broadly positive: 25 analysts rate the stock Buy and two rate it Hold, for a consensus “Moderate Buy” rating and a $596.44 price target.
  • MarketBeat previews the top five stocks to own by December 1st.

Advisors Asset Management Inc. purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 75,409 shares of the pharmaceutical company's stock, valued at approximately $39,425,000.

A number of other institutional investors also recently bought and sold shares of the business. Private Wealth Asset Management LLC lifted its stake in Vertex Pharmaceuticals by 152.4% during the third quarter. Private Wealth Asset Management LLC now owns 1,012 shares of the pharmaceutical company's stock worth $554,000 after purchasing an additional 611 shares during the last quarter. Greenline Wealth Management LLC acquired a new position in Vertex Pharmaceuticals in the third quarter valued at approximately $269,000. Westpac Banking Corp increased its stake in Vertex Pharmaceuticals by 2.4% in the third quarter. Westpac Banking Corp now owns 2,676 shares of the pharmaceutical company's stock valued at $1,399,000 after purchasing an additional 62 shares during the last quarter. Private Advisor Group LLC increased its stake in Vertex Pharmaceuticals by 64.5% in the third quarter. Private Advisor Group LLC now owns 6,793 shares of the pharmaceutical company's stock valued at $3,551,000 after purchasing an additional 2,663 shares during the last quarter. Finally, Hartford Funds Management Co LLC increased its stake in Vertex Pharmaceuticals by 2.9% in the third quarter. Hartford Funds Management Co LLC now owns 3,382 shares of the pharmaceutical company's stock valued at $1,769,000 after purchasing an additional 96 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Vertex Pharmaceuticals

Here are a few of the latest headlines about VRTX:

  • Positive Sentiment: A growth-stock article pointed to Vertex’s strong results and deep pipeline as reasons for renewed investor interest. This is supportive commentary rather than a new company announcement. Article: Growth stocks to buy
  • Neutral Sentiment: Vertex is studying the at-home injector experience in an IgA nephropathy trial. The update concerns administration and patient experience; the supplied report does not cite new efficacy or safety results. Article: At-home injector study
  • Negative Sentiment: Directors Sangeeta Bhatia and Nancy Thornberry sold 271 and 1,000 shares, respectively. Both sales were made under pre-arranged Rule 10b5-1 plans, which makes them less clearly a signal of near-term concerns, but insider selling can weigh on sentiment. Article: Director share sale

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 271 shares of the business's stock in a transaction on Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $148,470.06. Following the sale, the director directly owned 4,653 shares in the company, valued at approximately $2,549,192.58. The trade was a 5.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of the business's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $547.86, for a total value of $547,860.00. Following the sale, the director directly owned 1,109 shares in the company, valued at $607,576.74. This trade represents a 47.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 16,557 shares of company stock valued at $9,071,071. 0.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on VRTX. Wells Fargo & Company raised their price objective on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an "overweight" rating in a report on Tuesday, November 3rd. Daiwa Securities Group upped their target price on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. UBS Group increased their target price on shares of Vertex Pharmaceuticals from $615.00 to $640.00 and gave the company a "buy" rating in a research report on Tuesday, November 3rd. Rothschild & Co Redburn lifted their price target on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Finally, Morgan Stanley cut their price target on shares of Vertex Pharmaceuticals from $665.00 to $660.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $596.44.

Check Out Our Latest Research Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $520.66 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 1.89. The firm has a market cap of $132.01 billion, a price-to-earnings ratio of 33.50, a price-to-earnings-growth ratio of 2.84 and a beta of 0.28. The firm's fifty day moving average price is $522.74 and its 200 day moving average price is $485.01. Vertex Pharmaceuticals Incorporated has a 1-year low of $412.27 and a 1-year high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to analysts' expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The firm's quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.80 EPS. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current year.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Further Reading

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?

Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines